The World Federation of Hemophilia (WFH) is proud to announce the launch of Clinical Advances in Gene Therapy for Hemophilia, an online continuing medical education...
As recently announced, the World Federation of Hemophilia (WFH) has joined a collaboration led by the American Society of Hematology (ASH), which also includes the...
The World Federation of Hemophilia (WFH) has joined a collaboration led by the American Society of Hematology (ASH), which also includes the International Society on...
Please note that LFB BIOMEDICAMENTS has issued an alert concerning a defect in the quality appearance of the water for injection (vials 2.5ml, 5ml and...
The World Federation of Hemophilia (WFH) is pleased to showcase the Diagnosis of Hemophilia and Other Bleeding Disorders: A Laboratory Manual, the definitive how-to guide...
On December 12, 2017, the WFH hosted a webinar for people across the globe interested in learning more about participating in the WFH World Bleeding...
Roche has reported that a young patient in the HAVEN 2 clinical trial for Hemlibra (emicizumab) has developed an anti-drug antibody to Hemlibra resulting in...
Update from Roche on Hemlibra (emicizumab), for more information please click here.
Update: On March 28, 2018, Chugai Pharmaceuticals, a subsidiary of Roche, announced that a Japanese court ruled that the hemophilia treatment product Hemlibra (emicizumab) does...
Determining the safety and quality of therapeutic products for the treatment of hemophilia is crucial for the optimal treatment of patients. The World Federation of...